RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

NCT02746744 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Rituximab
DRUG: Dimethyl fumarate
DRUG: Sodium Chloride solution

Sponsor

Anders Svenningsson